Summary
The Trump administration announced it is sending 100 cease-and-desist letters to pharmaceutical companies to stop them from running what it considers misleading ads. It also plans to close a loophole that has allowed some drug companies to hide important safety information in their ads. These actions aim to increase transparency and safety information in drug advertising.
Key Facts
- The Trump administration is sending 100 cease-and-desist letters to pharmaceutical companies over misleading ads.
- A new memorandum directs Health and Human Services to enforce transparency in drug ads.
- Thousands of warning letters from the FDA are also being sent to remove misleading ads.
- A loophole from 1997 allowed drug companies to hide important safety details by directing consumers to other sources.
- The administration's actions aim to improve public trust and safety by requiring full disclosure in ads.
- Trump's efforts to change drug advertising rules may face legal challenges.
- Disclosing all side effects in ads may increase their length and cost for companies.
